{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:03:34Z","timestamp":1783091014203,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":869,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01NS097197"],"award-info":[{"award-number":["P01NS097197"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-021-01040-7","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T10:03:06Z","timestamp":1617876186000},"page":"1414-1425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Targeting Gys1 with AAV\u2010SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models"],"prefix":"10.1016","volume":"18","author":[{"given":"Emrah","family":"Gumusgoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikran R","family":"Guisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahba","family":"Kasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Verhalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmistha","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1007\/s13311-021-01040-7_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1566524024605761","article-title":"Glycogen and its metabolism","volume":"2","author":"Roach","year":"2002","journal-title":"Curr Mol Med."},{"issue":"1","key":"10.1007\/s13311-021-01040-7_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tplants.2013.08.004","article-title":"Transition from glycogen to starch metabolism in Archaeplastida","volume":"19","author":"Cenci","year":"2014","journal-title":"Trends Plant Sci."},{"key":"10.1007\/s13311-021-01040-7_bib3","doi-asserted-by":"crossref","unstructured":"Sullivan MA, Nitschke S, Skwara EP, et al. Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases. Cell Rep. 2019;27(5):1334\u201344 e6.","DOI":"10.1016\/j.celrep.2019.04.017"},{"issue":"1","key":"10.1007\/s13311-021-01040-7_bib4","first-page":"11","article-title":"Familial cirrhosis of the liver with storage of abnormal glycogen","volume":"5","author":"Andersen","year":"1956","journal-title":"Lab Invest."},{"issue":"6","key":"10.1007\/s13311-021-01040-7_bib5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/ana.410440604","article-title":"Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene","volume":"44","author":"Lossos","year":"1998","journal-title":"Ann Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01040-7_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.gene.2012.12.065","article-title":"Abnormal glycogen in astrocytes is sufficient to cause adult polyglucosan body disease","volume":"515","author":"Dainese","year":"2013","journal-title":"Gene."},{"issue":"49","key":"10.1007\/s13311-021-01040-7_bib7","doi-asserted-by":"crossref","first-page":"33816","DOI":"10.1074\/jbc.M807428200","article-title":"Abnormal metabolism of glycogen phosphate as a cause for Lafora disease","volume":"283","author":"Tagliabracci","year":"2008","journal-title":"J Biol Chem."},{"issue":"24","key":"10.1007\/s13311-021-01040-7_bib8","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1073\/pnas.0503285102","article-title":"Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin","volume":"102","author":"Gentry","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"10.1007\/s13311-021-01040-7_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease - from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat Rev Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01040-7_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet."},{"issue":"2","key":"10.1007\/s13311-021-01040-7_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat Genet."},{"issue":"4","key":"10.1007\/s13311-021-01040-7_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet."},{"issue":"11","key":"10.1007\/s13311-021-01040-7_bib13","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/acn3.51211","article-title":"GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease","volume":"7","author":"Chown","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"issue":"3","key":"10.1007\/s13311-021-01040-7_bib14","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s12035-019-01842-z","article-title":"Reactive Glia-Derived Neuroinflammation: a Novel Hallmark in Lafora Progressive Myoclonus Epilepsy That Progresses with Age","volume":"57","author":"Lahuerta","year":"2020","journal-title":"Mol Neurobiol."},{"key":"10.1007\/s13311-021-01040-7_bib15","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/erm.2020.5","article-title":"Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities","volume":"22","author":"Sanz","year":"2020","journal-title":"Expert Rev Mol Med."},{"issue":"5","key":"10.1007\/s13311-021-01040-7_bib16","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s12035-016-9884-4","article-title":"Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models","volume":"54","author":"Lopez-Gonzalez","year":"2017","journal-title":"Mol Neurobiol."},{"key":"10.1007\/s13311-021-01040-7_bib17","doi-asserted-by":"crossref","first-page":"105173","DOI":"10.1016\/j.nbd.2020.105173","article-title":"Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity","volume":"147","author":"Varea","year":"2021","journal-title":"Neurobiol Dis."},{"issue":"3","key":"10.1007\/s13311-021-01040-7_bib18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s12035-020-02170-3","article-title":"Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress","volume":"58","author":"Sinha","year":"2021","journal-title":"Mol Neurobiol."},{"key":"10.1007\/s13311-021-01040-7_bib19","article-title":"Ppp1r3d deficiency preferentially inhibits neuronal and cardiac Lafora body formation in a mouse model of the fatal epilepsy Lafora disease","author":"Israelian","year":"2020","journal-title":"J Neurochem."},{"key":"10.1007\/s13311-021-01040-7_bib20","article-title":"An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice","author":"Nitschke","year":"2020","journal-title":"J Biol Chem."},{"issue":"11","key":"10.1007\/s13311-021-01040-7_bib21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/11.11.1251","article-title":"Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice","volume":"11","author":"Ganesh","year":"2002","journal-title":"Hum Mol Genet."},{"issue":"6","key":"10.1007\/s13311-021-01040-7_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.22156","article-title":"Glycogen hyperphosphorylation underlies lafora body formation","volume":"68","author":"Turnbull","year":"2010","journal-title":"Ann Neurol."},{"issue":"23","key":"10.1007\/s13311-021-01040-7_bib23","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1093\/hmg\/ddv385","article-title":"A novel mouse model that recapitulates adult-onset glycogenosis type 4","volume":"24","author":"Orhan Akman","year":"2015","journal-title":"Hum Mol Genet."},{"issue":"2","key":"10.1007\/s13311-021-01040-7_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","article-title":"Inhibiting glycogen synthesis prevents Lafora disease in a mouse model","volume":"74","author":"Pederson","year":"2013","journal-title":"Ann Neurol."},{"issue":"3","key":"10.1007\/s13311-021-01040-7_bib25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann Neurol."},{"issue":"12","key":"10.1007\/s13311-021-01040-7_bib26","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum Mol Genet."},{"issue":"4","key":"10.1007\/s13311-021-01040-7_bib27","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-019-09849-y","article-title":"Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders","volume":"14","author":"Raikwar","year":"2019","journal-title":"J Neuroimmune Pharmacol."},{"issue":"5","key":"10.1007\/s13311-021-01040-7_bib28","first-page":"341","article-title":"CRISPR for Neuromuscular Disorders: Gene Editing and Beyond","volume":"34","author":"Young","year":"2019","journal-title":"Physiology (Bethesda)."},{"key":"10.1007\/s13311-021-01040-7_bib29","doi-asserted-by":"crossref","first-page":"118165","DOI":"10.1016\/j.lfs.2020.118165","article-title":"CRISPR\/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases","volume":"259","author":"Karimian","year":"2020","journal-title":"Life Sci."},{"issue":"9","key":"10.1007\/s13311-021-01040-7_bib30","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat Biotechnol."},{"issue":"7546","key":"10.1007\/s13311-021-01040-7_bib31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature."},{"issue":"7","key":"10.1007\/s13311-021-01040-7_bib32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/hum.2016.013","article-title":"Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease","volume":"27","author":"Karumuthil-Melethil","year":"2016","journal-title":"Hum Gene Ther."},{"key":"10.1007\/s13311-021-01040-7_bib33","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Clement","year":"2016","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1007\/s13311-021-01040-7_bib34","doi-asserted-by":"crossref","unstructured":"Kawasaki H, Kosugi I, Sakao-Suzuki M, et al. Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain. J Vis Exp. 2016(113). https:\/\/doi.org\/10.3791\/54164","DOI":"10.3791\/54164-v"},{"issue":"7","key":"10.1007\/s13311-021-01040-7_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods."},{"issue":"12","key":"10.1007\/s13311-021-01040-7_bib36","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41592-019-0582-9","article-title":"ilastik: interactive machine learning for (bio)image analysis","volume":"16","author":"Berg","year":"2019","journal-title":"Nat Methods."},{"issue":"43","key":"10.1007\/s13311-021-01040-7_bib37","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1074\/jbc.RA120.015061","article-title":"Sensitive quantification of alpha-glucans in mouse tissues, cell cultures, and human cerebrospinal fluid","volume":"295","author":"Nitschke","year":"2020","journal-title":"J Biol Chem."},{"key":"10.1007\/s13311-021-01040-7_bib38","unstructured":"Lowry O, Passonneau JV. A Flexible System of Enzymatic Analysis. 2012."},{"issue":"1","key":"10.1007\/s13311-021-01040-7_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.106.115550","article-title":"Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*, S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)pro pyl]-1H-indole-2-carboxamide)","volume":"321","author":"Suh","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1007\/s13311-021-01040-7_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fncel.2015.00431","article-title":"Role of brain glycogen in the response to hypoxia and in susceptibility to epilepsy","volume":"9","author":"Lopez-Ramos","year":"2015","journal-title":"Front Cell Neurosci."},{"issue":"7","key":"10.1007\/s13311-021-01040-7_bib41","doi-asserted-by":"crossref","first-page":"906","DOI":"10.15252\/emmm.201707608","article-title":"Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease","volume":"9","author":"Nitschke","year":"2017","journal-title":"EMBO Mol Med."},{"issue":"4","key":"10.1007\/s13311-021-01040-7_bib42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.devcel.2015.01.035","article-title":"Genetic changes shaping the human brain","volume":"32","author":"Bae","year":"2015","journal-title":"Dev Cell."},{"issue":"1","key":"10.1007\/s13311-021-01040-7_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11011-020-00630-2","article-title":"Crossing the blood-brain barrier with AAV vectors","volume":"36","author":"Liu","year":"2021","journal-title":"Metab Brain Dis."},{"key":"10.1007\/s13311-021-01040-7_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.brainres.2011.03.014","article-title":"Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors","volume":"1389","author":"Miyake","year":"2011","journal-title":"Brain Res."},{"issue":"1","key":"10.1007\/s13311-021-01040-7_bib45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymthe.2020.09.033","article-title":"AAV9 Gene Therapy Increases Lifespan and Treats Pathological and Behavioral Abnormalities in a Mouse Model of CLN8-Batten Disease","volume":"29","author":"Johnson","year":"2021","journal-title":"Mol Ther."},{"key":"10.1007\/s13311-021-01040-7_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13059-015-0817-8","article-title":"Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications","volume":"16","author":"Friedland","year":"2015","journal-title":"Genome Biol."},{"issue":"16","key":"10.1007\/s13311-021-01040-7_bib47","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther."},{"issue":"26","key":"10.1007\/s13311-021-01040-7_bib48","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","article-title":"Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo","volume":"10","author":"McCarty","year":"2003","journal-title":"Gene Ther."},{"key":"10.1007\/s13311-021-01040-7_bib49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1\u20132","key":"10.1007\/s13311-021-01040-7_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-1119(02)00878-8","article-title":"Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites","volume":"297","author":"Tornoe","year":"2002","journal-title":"Gene."},{"issue":"24","key":"10.1007\/s13311-021-01040-7_bib51","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1016\/j.febslet.2009.10.036","article-title":"Correlation of mRNA and protein in complex biological samples","volume":"583","author":"Maier","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1007\/s13311-021-01040-7_bib52","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-021-02285-1","article-title":"Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model","author":"Molla","year":"2021","journal-title":"Mol Neurobiol."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01040-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01040-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01040-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:51:38Z","timestamp":1761807098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1878747923011716"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01040-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.12.430952","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Gys1 with AAV\u2010SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01040-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}